BiotechTube
Home/Glaukos/Thomas W. Burns
TW

Thomas W. Burns

Chairman & Chief Executive Officer

Glaukos

Therapeutic Areas

GlaucomaCorneal DisordersRetinal Diseases

Glaukos Pipeline

DrugIndicationPhase
iStent inject® WPrimary Open-Angle GlaucomaCommercial
iStent infinite®Refractory Primary Open-Angle GlaucomaCommercial
iDose® TR (travoprost implant)Glaucoma / Ocular HypertensionCommercial Launch
iLink® V / EpioxaProgressive Keratoconus / Corneal EctasiaCommercial
Next-Gen MIGS DevicesGlaucomaDevelopment
Retinal Sustained-Drug Delivery PlatformRetinal Diseases (e.g., DME, RVO)Preclinical/Early Development

Leadership Team at Glaukos

JE
Joseph E. Gilliam
Chief Financial Officer
R(
Robert (Bob) A. Kammer, M.D.
Chief Medical Officer
CC
Chris Calcaterra
Chief Commercial Officer
A(
Aleksandra (Ola) Sokolowski, Ph.D.
Chief Scientific Officer & SVP, Corporate Development
View full Glaukos profile